Overview

Role of Sildenafil for Fontan Associated Liver Disease (SiFALD) Study

Status:
Completed
Trial end date:
2019-06-30
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if the medication, sildenafil (also known as Revatio), can slow or stop the progression of liver disease in patients who previously had a Fontan operation.
Phase:
Phase 3
Details
Lead Sponsor:
Mayo Clinic
Treatments:
Sildenafil Citrate